Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. by Cristillo, Anthony D et al.
LSHTM Research Online
Cristillo, Anthony D; Bristow, Claire C; Peeling, Rosanna; Van Der Pol, Barbara; de Cortina,
Sasha Herbst; Dimov, Ivan K; Pai, Nitika Pant; Jin Shin, Dong; Chiu, Ricky YT; Klapperich,
Catherine; +3 more... Madhivanan, Purnima; Morris, Sheldon R; Klausner, Jeffrey D; (2017)
Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Trans-
mitted Infection-Clinical Trial Group Programmatic Meeting. [Conference or Workshop Item]
https://doi.org/10.1097/OLQ.0000000000000572
Downloaded from: http://researchonline.lshtm.ac.uk/4652934/
DOI: https://doi.org/10.1097/OLQ.0000000000000572
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
Point-of-Care Sexually Transmitted Infection
Diagnostics: Proceedings of the STAR Sexually
Transmitted Infection—Clinical Trial Group
Programmatic Meeting
Anthony D. Cristillo, PhD, MS,* Claire C. Bristow, PhD, MPH, MSc,† Rosanna Peeling, PhD,‡
Barbara Van Der Pol, PhD, MPH,§ Sasha Herbst de Cortina, BA,¶|| Ivan K. Dimov, PhD,**
Nitika Pant Pai, MD, MPH, PhD,†† Dong Jin Shin, BSE,‡‡ Ricky Y.T. Chiu, PhD,¶||
Catherine Klapperich, PhD,§§ Purnima Madhivanan, MD, MPH, PhD,||¶
Sheldon R. Morris, MD, MPH,† and Jeffrey D. Klausner, MD, MPH¶||
Abstract: The goal of the point-of-care (POC) sexually transmitted infec-
tion (STI) Diagnostics meeting was to review the state-of-the-art research
and develop recommendations for the use of POC STI diagnostics. Experts
from academia, government, nonprofit, and industry discussed POC diag-
nostics for STIs such as Chlamydia trachomatis, human papillomavirus,
Neisseria gonorrhoeae, Trichomonas vaginalis, and Treponema pallidum.
Key objectives included a review of current and emerging technologies,
clinical and public health benefits, POC STI diagnostics in developing
countries, regulatory considerations, and future areas of development.
Key points of the meeting are as follows: (i) although some rapid point-
of-care tests are affordable, sensitive, specific, easy to perform, and deliver-
able to those who need them for select sexually transmitted infections,
implementation barriers exist at the device, patient, provider, and health
system levels; (ii) further investment in research and development of
point-of-care tests for sexually transmitted infections is needed, and
new technologies can be used to improve diagnostic testing, test uptake,
and treatment; (iii) efficient deployment of self-testing in supervised
(ie, pharmacies, clinics, and so on) and/or unsupervised (ie, home, of-
fices, and so on) settings could facilitate more screening and diagnosis
that will reduce the burden of sexually transmitted infections; (iv) de-
velopment of novel diagnostic technologies has outpaced the genera-
tion of guidance tools and documents issued by regulatory agencies;
and (v) questions regarding quality management are emerging includ-
ing the mechanism by which poor-performing diagnostics are removed
from the market and quality assurance of self-testing is ensured.
POC Diagnostics
Consistent with the National Institutes of Health's defini-
tion of point-of-care (POC) diagnostics,1 the authors consider
POC tests to be those that allow patient diagnoses outside of a typ-
ical clinical laboratory. Such tests include those that can be exe-
cuted in a physician's office, hospital bedside, at the patient's
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home, or in the field. Point-of-care testing facilitates the provision
of rapid treatment and care to the patient. Some of the desired at-
tributes of POC sexually transmitted infection (STI) tests include
(i) accuracy (>95%), (ii) ease of use/minimal training required,
(iii) rapid turnaround time (while the patient is still accessible),
(iv) low cost, and (v) portability. Historically, there have been
rapid POC tests to aid in sexually transmitted disease diagnosis
such as the Gram stain (Neisseria gonorrhoeae [NG]), rapid
plasma reagin (syphilis), POC microscopy (trichomoniasis), vag-
inal whiff (bacterial vaginosis [BV]), pH testing, and POC mi-
croscopy with and without potassium hydroxide for vaginal
candidiasis and BV. Those tests are widely used in a variety of
clinical settings, and although they can be considered POC tests,
they were outside the scope of our discussion.
The Need for POC STI Diagnostics
Chlamydia trachomatis (CT), human papillomavirus
(HPV), N. gonorrhoeae, Trichomonas vaginalis (TV), and Trepo-
nema pallidum (TP), among themost common causes of STIs, con-
tributed approximately 357 million new STI cases globally in 2012.
In 2012, there were 131 million cases of CT, 78 million cases of
NG, 143 million cases of TV, and 5.6 million cases of syphilis,
caused by T. pallidum.2 In addition, more than 290 million women
have an HPV infection, which leads to cervical cancer.2 Early and
accurate diagnosis of infection is important to provide patients with
timely, appropriate, and effective treatment, thereby, limiting the
spread and adverse outcomes of infection. Approximately 80% of
the newly reported STI cases occur in developing countries, and
they disproportionately impact women.3 Many STI patients are
asymptomatic andmay be identified only through screening.4With-
out accurate tests, these asymptomatic cases could remain unknow-
ingly chronically infected and untreated for an extended period of
time, resulting in long-term reproductive complications and further
spread of infections to others.
Consistent with the 2030 Agenda for Sustainable Develop-
ment, the World Health Organization (WHO) has developed draft
global health sector guidance on STIs.5 The three draft strategies
included (i) universal health coverage, (ii) the continuum of health
services, and (iii) the public health approach. Each strategywas es-
tablished with a vision, a goal, targets, and actions towards elimi-
nating STIs as public health threats, and actions to be taken by
countries, WHO, and partners. Point-of-care diagnostics can facil-
itate achievement of the vision set forth for STIs in those sustain-
able development goals.
Reproductive and Maternal Health
Although common among pregnant women, STIs such as
CT and NG may lead to adverse birth outcomes.6,7 Syphilis, CT,
NG, and TV in pregnancy can cause fetal death, stillbirth, low
birth weight, preterm birth, fetal growth retardation, neonatal
death, and infections in infants.6,8–11 STI screening and treatment
in pregnancy can prevent such adverse outcomes.8,12–14 Detection
and treatment of CT during pregnancy have been shown to reduce
ocular disease in newborns, and treatment of NG during preg-
nancy reduces pregnancy-related complications.15,16 Challenges
still remain in the uptake of screening, the availability of diagnos-
tics, and screening policies for antenatal care in developing coun-
tries. For example, a 2015 Progress Report for the Implementation
of the Global Strategy for Prevention and Control of Sexually
Transmitted Infections: 2006–2015 reported that the median per-
centage of antenatal care attendees who were tested for syphilis
remained largely unchanged from 2008 (59%) to 2013 (58%) in
the WHO African region.17 Furthermore, in the WHO Eastern
Mediterranean region, many countries had no syphilis
diagnostic tests or screening policies for pregnant women be-
cause of a perceived low incidence.17 However, syphilis screen-
ing in antenatal care has been shown to be cost-effective even in
low prevalence settings.18
Lack of Access, Equipment, and Trained Personnel
Although STI diagnostic tests are available and used in
high-income countries, they are largely unavailable in low- to
middle-income countries where there is a lack of equipment and
trained personnel required for etiological diagnosis of STIs.2,19,20
Additional challenges associated with current diagnostics include
high cost of available tests and delayed turnaround time for pa-
tients to receive results. However, POC STI diagnostics that are
available for syphilis are accurate, easy to use, and provide rapid
results.21 Hence, extending the reach of such POC diagnostics
would have a significant impact on early STI diagnosis and treat-
ment if implemented in national, regional or district laboratories,
primary care facilities and clinics, bedside, nonfacility-based com-
munity outreach programs, and within homes. The success of
POC syphilis screening underscores the necessity to deliver POC
screening to all major STIs.
Etiological Versus Syndromic Management
To date, STI etiological diagnosis and management has
been challenging. Although standard nucleic acid amplification
instruments have become smaller and methods are near real time,
such tests can be technically challenging and require expensive
equipment and skilled laboratory or medical staff. Such resources
are not easily available in low- to middle-income countries. Hence,
syndromic management continues to be the primary approach rec-
ommended by public health professionals for STI treatment.
17,22,23 STI syndromic management is based on the identification
of several easily recognized signs and symptoms. However, this
approach lacks specificity and symptoms may reflect nonsexually
transmitted conditions.24 That approach could lead to inappropri-
ate overtreatment, resulting in antimicrobial resistance, continued
transmission, and unnecessary drug toxicity. Syndromic manage-
ment also does not address asymptomatic infections, which are
of public health concern. Given its low specificity and sensitivity,
syndromic management is unlikely to impact the burden of dis-
ease. By contrast, the development of highly specific and sensitive
POC STI diagnostics could facilitate a departure from syndromic
management in favor of etiological management of STIs. Such di-
agnostics could facilitate appropriately targeted treatments be-
cause of rapid specific STI detection, sparing unnecessary use of
antimicrobials that may contribute to resistance. By implementing
a POC diagnostics screening program, progress would also be
made to identify infected asymptomatic patients.
POC STI Diagnostics and Unique
Challenges/Considerations for
Developing Countries
A lack of access to medical facilities and affordable testing
are likely reasons why STI services fail. In countries such as
Benin, Bolivia, Chad, Haiti, Madagascar, Niger, Tanzania, Uganda,
and Zimbabwe, patients must often travel 4.7 km or more to access
the nearest medical facility.25 Relative inaccessibility of medical fa-
cilities raises the concern that, if treatment is not provided during a
diagnostic visit, loss to follow-up is highly likely. Thus, even in coun-
tries where diagnostic testing is available, limitations of accessibility
restrict the number of STI patients who can benefit from early diag-
nosis and treatment.
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While trying to satisfy the overall goals of quality, timeli-
ness, reliability, and cost, one needs to be aware of tradeoffs be-
tween performance and cost when assessing POC STI diagnostics
for use in resource-limited settings. Experts within the program-
matic meeting cited the ASSURED (A = affordable; S = sensitive;
S = specific; U = user-friendly; R = rapid and robust; E = equipment
free; D = deliverable) criteria as a useful approach to evaluate POC
STI diagnostics.26 In more urban settings, accuracy could be con-
sidered amore important factor as comparedwith cost or rapid turn-
around time for results.26,27 By contrast, in more rural settings, cost
and the delivery of rapid results could outweigh accuracy. To that
end, a less sensitive but more accessible test may be more easily de-
ployed and impactful in places where individuals may not currently
have access to any STI diagnostics.
CURRENT STATE OF POC STI DIAGNOSTICS
A number of POC STI diagnostic platforms are available
and provide results within 25 to 90 minutes; however, their perfor-
mance is quite variable.28–39 Diagnostic platforms include antibody
and antigen detection assays as well as nucleic acid amplification
tests (NAATs). Such tests include immuno-chromatographic tests
such as ACON Chlamydia and ACON NG/CT tests (ACON Lab-
oratories, San Diego, Calif ); BioRapid Chlamydia Ag Test (Biokit
S.A., Barcelona, Spain); Chlamydia Rapid Test SAS (Diagnostics
for Real World, Cambridge, UK); Clearview Chlamydia (Alere,
Waltham, Md); Chlamydia test card (Ultimed Products, GmbH,
Germany); Ultimed NG Test and Chlamydia Ag Test Card
(Ahrensburg, Germany); QuickVue Chlamydia Rapid Test (Quidel
Corporation, San Diego, Calif ); and real-time polymerase chain re-
action (eg, Xpert CT/NG, Cepheid, Sunnyvale, Calif ) assays. Addi-
tional POC STI testing platforms include io CT, io CT/NG, and io
TV (Atlas Genetics Ltd, Trowbridge, UK), Trulab PCR CT/NG,
(Molbio/bigTec, Goa, India), Alere-I/Alere (CT/NG),28 and the col-
orimetric antigen-targeting OSOM rapid TV test (Sekisui Diagnos-
tics, LLC, Lexington, Md). Although sensitive and specific POC
tests are available for CT, NG, and TV, progress is needed to im-
prove availability and performance of some currently available
diagnostic tests.
POC Syphilis and HIV/Syphilis Dual Tests
There are several rapid POC tests for syphilis. These tests
are antibody detection lateral flow assays and include the Alere
Determine Syphilis TP, the SD BIOLINE Syphilis 3.0 test, and
the Chembio DPP Syphilis Screen & Confirm Assay. For whole
blood syphilis tests, sensitivity can range from 86.3% to 100%
and specificity, from 95.9% to 97.0%.40
Human immunodeficiency virus (HIV) and syphilis coin-
fection is increasingly common, and it has been found that syphilis
infection may facilitate HIV acquisition and transmission includ-
ing mother-to-child transmission of HIV.41–45 Dual POC rapid
tests detect antibodies to both HIV and T. palladium and have
the potential to simplify training, streamline procurement, ensure
testing for both HIVand syphilis, and improve patient experiences.
The similarities in screening recommendations for HIVand syph-
ilis offer an important opportunity to strengthen prevention pro-
grams for the elimination of congenital syphilis along with
prevention of HIV mother-to-child transmission by means of inte-
grated screening.30 Dual rapid HIV/syphilis tests make integrated
screening more feasible, and there are currently at least 5 manufac-
turers of these tests (Chembio Diagnostics Systems Inc, Medford,
NY; MedMira Inc, Halifax, Canada; Standard Diagnostics Inc,
Gyeonggi-do, Republic of Korea; Premier Medical Corp Ltd,
Watchung, NJ; bioLytical Laboratories, Inc, British Columbia,
Canada) and 1 dual assay prequalified byWHO (Alere SDBioline
HIV/Syphilis Duo Test).
Dual HIV/syphilis rapid tests use specific recombinant an-
tigens, which form an antigen-antibody complex when specific
HIV and/or syphilis antibodies are present in the specimen. Such
POC tests use finger stick whole blood sample and a single device
to test for both HIV and syphilis in minutes. Evaluations of dual
HIV/syphilis tests revealed that HIV sensitivity can range from
95% to 100% in the laboratory30–36 and 91% to 99% in field set-
tings.37,38 Human immunodeficiency virus specificity can range
from 94% to 100% in the laboratory and 97% to 100% in the
field.37,39 Treponemal sensitivity in the same dual HIV/syphilis
tests can range from 87% to 100% in the laboratory and 80% to
96% in the field; treponemal specificity can range from 93% to
100% in the laboratory and 91% to 100% in the field. Relative
to single testing strategies, dual HIV/syphilis tests demonstrated
good performance, fewer finger pricks and/or blood draws, in-
creased efficiencies in service delivery (eg, time saving, stream-
lined procurement, ensured testing for 2 infections for every
patient), and greater cost-effectiveness.46 Treponemal antibodies
can persist for life; therefore, in settings where there is high prev-
alence of previously treated syphilis, such as in men who have sex
with men (MSM) populations, confirmatory tests may be needed
before treatment initiation. In some settings, such as in resource-
limited areas and in antenatal care, the risk of untreated infection
may outweigh the risk of unnecessary treatment. In addition to
dual tests for HIV and syphilis, there is a need in some settings,
in particular in Asia where hepatitis B is endemic, for triplex as-
says to detect HIV, syphilis, and hepatitis B infection.47 The eval-
uation of multiplex testing algorithms in antenatal care settings is
urgently needed.48
POC tests for CT, NG, and TV
Among current POC tests for CT, NG, and TV, Cepheid's
NG/CT GeneXpert assay uses multiplex, rapid real-time polymer-
ase chain reaction and fluorescence detection. Point-of-care testing
for those STIs can also be accomplished by lateral flow immu-
noassays (LFAs) such as the aQcare Chlamydia TRF test
(Medisensor Inc, Seoul, Korea), QuickVue CT, and QuickVue
TV test (Quidel Corporation, San Diego, Calif ).28,29 For all POC
CT tests, sensitivity can range from 17.1% to 98.7%, whereas
specificity can range from 91.3% to 100%.28 In a literature review
of NG and TV tests, it was found that sensitivity can range from
12.5% to 100%49,50 and 38% to 98%,51–53 respectively, whereas
specificity can range from 93% to 100%50,54,55 and 99.3% to
100%,51,56 respectively.28 Although there are sensitive and spe-
cific tests for CT (GeneXpert, aQcare Chlamydia TRF), NG
(GeneXpert), and TV (OSOM), the implication of the wide sensi-
tivity ranges across different tests is missed infections and contin-
ued transmission to partners and unborn children.
NEW STI POC DIAGNOSTICS AND APPROACHES
Enhanced CT Lateral Flow Assay
Honesti (Phase Diagnostics, Santa Ana, Calif ) is a new,
simple, rapid, handheld POC diagnostic for the detection of CT in-
fection.57 Although the device is based on the conventional LFA, it
additionally incorporates a novel target concentration mechanism
to overcome the sensitivity limitations of other lateral flow tests
for CT. Concentration of the target is accomplished by using a pro-
prietary aqueous two-phase system that enriches the target bio-
marker before detection, significantly improving the detection
limit of conventional LFAs. These aqueous two-phase system
components are inexpensive, require no additional power source,
Point-of-Care Sexually Transmitted Infection Diagnostics
Sexually Transmitted Diseases • Volume 44, Number 4, April 2017 213
and are integrated such that no additional training is required.
From the end user's point of view, the device is performed no dif-
ferent from the conventional LFA (eg, pregnancy test), allowing
for self-sample collection and colorimetric readout in less than
10 minutes. Proof-of-concept studies have been conducted on
clinical CT samples, bacteria, viruses, proteins, and small mole-
cules.57–59 Given its unique targeted concentration mechanism,
Honesti could provide detection of CT in patient samples with
low CT concentrations; however, clinical trials are urgently
needed to validate this. This simple platform has the potential to
increase screening access and enable true same visit testing and
treatment in decentralized settings.
Cell Phone-Based DNA CT Test
In conventional lateral flow processing, fluids move
through the system, whereas the analyte(s) stays in place. A drop-
let magnetofluidic process has been developed, whereby the fluid
stays in place and the analyte moves through the system.60,61 This
principle uses reagents in the form of aqueous drops, sealed in
immiscible oil. The structural/surface energy-based trapping facil-
itates droplet isolation, and hydrophobic surfaces facilitate trans-
port of magnetic beads on planar surfaces. Potential benefits of
this new fluid processing are that it is compatible with reagents
and assays as well as that its simple design is amenable to use with
low-cost instrumentation. MobiNAAT, a cell phone-based DNA
CT test, integrates a mobile telephone and a cartridge, which
serves as the processing unit for a loop-mediated isothermal am-
plification assay. The cartridge is responsible for (i) thermal incu-
bation, (ii) magnetic particle handling, and (iii) optical path
imaging. The cartridge facilitates sample processing coordination
and optical signal preprocessing. A mobile phone provides the
user interface (UI), video tutorials, and data acquisition/signal pro-
cessing through the phone's camera. The user can use a mobile ap-
plication to assist with platform workflow. In a retrospective study
of vaginal swabs for CT, 20 archived dry vaginal swabs (10 posi-
tive and 10 negative) were tested using the MobiNAAT technol-
ogy. Investigators at Johns Hopkins University found that results
were in full agreement with the reference results (unpublished
data). An on-site evaluation of the test at the Johns Hopkins Uni-
versity Emergency Department found that MobiNAAT could pro-
duce CT test results in approximately 1 hour, whereas central
laboratory testing required 80 hours to yield comparable results
(unpublished data). In addition, the costs associated with that test
are much lower than those of standard POC NAATs. Given that
MobiNAATuses a smartphone and small cartridge, it requires sig-
nificantly less space than a typical POC NAAT. In resource-
limited settings, where there is a lack of infrastructure to imple-
ment POC diagnostics that require specialized training, expensive
equipment, and/or laboratory infrastructure, the widespread avail-
ability of smartphones could makeMobiLab tests a feasible means
to facilitate POC diagnostic testing.
Other Key Innovations
To make molecular diagnostics more readily available in de-
veloping countries, disposablemolecular diagnostic systems that can
be used via a smartphone are currently being developed. Three key
areas of innovations include (i) self-powered microfluidic flow, (ii)
robust sample preparation, and (iii) diagnostic assays with sensitive
visual readouts. To those ends, integrated universal sample prepara-
tion modules are being developed using microsedimentation-based
cell separation, reagent-free electrochemical cell lysis on a chip,
and pumpless degas flow. Other innovations include miniaturiza-
tion using Nanowire/Nanodot technologies, which offer sensitive
pathogen detection with minimal sample collection. Nanowire
technologies have been used to detect malaria parasites, distin-
guish different species, and identify drug resistance using a
finger-pricked sample of blood within 20 minutes.
Paper Fluidic Diagnostics or Paper-Plastic Hybrid
Molecular Diagnostics for CT/NG
Over the past 5 years, efforts to improvemolecular diagnos-
tics for CTandNG have not only focused onmicrofluidic diagnos-
tics but have used paper fluidic or paper-plastic hybrid molecular
diagnostics. Such molecular tests have targeted human papilloma-
virus and tried to produce same day results that could be read with-
out instrumentation. To accomplish these goals, Klapperich and
coworkers have developed a method of extracting nucleic acids
into a planar platform/two-dimensional layout and have applied
this technology to extract nucleic acid from human samples.62
Once a swab is collected, it is placed in a buffer that facilitates
nucleic acid extraction onto a membrane. Once extracted, nucleic
acids are amplified. For that, a number of isothermal amplification
techniques including helicase dependent amplification have been
incorporated onto the planar platform. Standard LFA technology
allows this test to produce a nonquantitative, “positive/negative”
result that is visible on paper. Klapperich and coworkers are also
developing a similar test for NG and are working toward a
multiplexing assay to detect both CTand NG. Currently, to obtain
results, the user must perform sample collection, washing, and elu-
tion. Ongoing efforts are aimed at reducing the number of steps in-
volved and to reduce the overall turnaround time from less than
1 hour to 15 minutes.
Simple Steps: Optimizing Diagnostic Strategies by
Adding Vaginal pH to Testing Algorithms
In settings where new diagnostic tests could take several
years to successfully implement, existing tools such as pH testing
can be incorporated to enhance syndromic management. The pH
of the upper vagina is normally acidic (pH level of 3.8 to 4.5),
whereas bacterial overgrowth in BVand trichomonas can increase
vaginal pH higher than 4.5. Elevated vaginal pH can therefore
serve as a marker for BVor TV infection. A study conducted in
India, in which 898 sexually active adult women were screened
for reproductive tract infections, found that vaginal pH and
whiff test together correctly diagnosed 82% of laboratory-
diagnosed BV cases versus 40% with syndromic management
and 83% of laboratory-diagnosed TV infections versus 51%
with syndromic management.63
Clarke and coworkers found that elevated vaginal pH was
associated with greater risk of infection with multiple HPV types
in women younger than 35 years and older than 65 years.64 There-
fore, in settings where visual inspection is used in lieu of Pap
smears, the addition of vaginal pH could potentially assist in the
detection of HPV in women within these age groups. Additional
studies in Israel and Africa have shown that vaginal pH testing
could improve the diagnosis of vaginal candidiasis.65 As such,
an algorithm combining vaginal pH testing and subjective evalua-
tion of discharge could have a higher sensitivity and specificity
than the WHO syndromic management testing strategy.
POC Diagnostics and New Approaches to
Self-Testing
Problems associated with conventional testing include so-
cial visibility, a lack of confidentiality, and long turnaround times
for results and treatment, as well as stigma and discrimination.
Such problems are not restricted to developing countries but re-
flect global issues associated with conventional testing. Self-
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testing could mitigate those issues by providing confidential and
convenient testing that is personalized and affordable. Self-
testing could provide links to care with a shorter turnaround time
than conventional testing. Two types of self-test strategies are:
(i) unsupervised and (ii) facilitated/supervised self-testing. In un-
supervised self-testing, users understand the pretest information,
conduct and interpret the self-test, and follow through on results
themselves. In facilitated testing, the self-testing is conducted by
the participant with the aid of counselors in a supervised setting.66
A unique form of facilitated testing through self-collection is
available in settings such as the Dean Street Express clinic in
London's SoHo district. In that site, asymptomatic persons can
(i) register, receive risk-based screening recommendations, and
obtain specimen labels via touch screen computers; (ii) perform
their own specimen collection in clinic bathrooms; (iii) submit
specimens for testing (Cepheid's GeneXpert CT/NG) via a pres-
surized air tube system; and (iv) obtain texted results via short
message service for CT or NG in less than 6 hours. Such unique
approaches to leverage technology to facilitate confidential self-
testing have proven successful in reducing the time to treatment.67
Although self-collection and the use of Xpert tests may be appropri-
ate in resource-rich countries, their implementation in resource-
poor nations may be more challenging. Although self-testing for
HIV is being widely promoted and supported by funders, national
control programs are encountering issues with regulatory approval
and linkage to care.68 Progress made in resolving these challenges
will facilitate self-testing for STIs.
GENERAL POC CHALLENGES
Given that there are POC tests with widely varying sensitiv-
ities,28 countries are challenged to identify and select the best plat-
forms for their sites. New accurate technologies for POC STI tests,
especially for use during pregnancy, are urgently needed. Cost-
effectiveness studies could serve as a tool to help policy makers
identify the interventions, which maximize health resources avail-
able in their setting and improve resource allocation and manage-
ment activities. In public health settings, choices must be made
about which health strategies to use; a cost-effectiveness analysis
can provide evidence about how to prioritize resources.
IMPLEMENTATION BARRIERS
Although POC testing can significantly impact global
health, barriers to implementation exist at the device, patient, pro-
vider, and health system levels.69 At the device level, barriers
include a lack of assay robustness and accuracy, a lack of integra-
tion of multiple tests targeting different pathogens, and difficulties
in performing and interpreting the POC test. At the patient level,
barriers include costs for confirmatory tests, difficulties in per-
forming the POC test, distrust, lack of awareness, privacy issues,
and/or a preference for conventional approaches.69 At the provider
level, barriers include costs, a lack of awareness, complicated pro-
tocols, challenges in workflow, or simply a resistance to adopting
POC diagnostics. At the health system level, barriers include costs,
integration challenges, quality assurance and quality control re-
quirements, workflow challenges, required training, and technical
support.69 Among the workflow challenges that could arise is the
reporting of notifiable STIs. In the United States, such reporting
is currently performed by clinical laboratories.
REGULATORY CHALLENGES OF NEW
TECHNOLOGY POCS
To meet global public health needs, new technologies that
facilitate development of POC STI diagnostics have emerged.
Although some of those tests are focused on single pathogen
detection, others leverage multiplexing technologies. However,
development of new technologies has outpaced the generation of
guidance tools and documents by regulatory agencies. Although
some guidance documents exist for POC STI diagnostics, those
recommendations are based on older technology.70 Different tech-
nologies yield different results, and performance (eg, sensitivity) is
dependent on the technology deployed. Questions therefore remain
as towhat constitutes acceptable performance given the tension be-
tween where a POC diagnostic is needed and how it will be used.
Therefore, factors such as accuracy and access must be considered
when deciding how multiplex devices will be evaluated.48,71 The
current environment may also not be ideal to newly developed as-
says. As the field continues to move forward at a rapid pace, ques-
tions are emerging regarding quality management. One question,
for example, is who would be responsible for maintaining and cal-
ibrating controls as well as deciding the fate for existing STI tests
that are not performing well or can be replaced with newer plat-
forms.72 Other issues that will require clarification and guidance
include difficulties with limits of detection and with inclusivity ex-
periments. Verification of off-label use for existing POC STI tests
will also require some inputs from regulatory agencies.
Many POC assays are available outside the United States,
and although some have reasonable diagnostic performance, the
majority of tests do not. This is especially true for developing
countries where cost is of paramount importance. From a public
health perspective, it may be beneficial to have many assays avail-
able because they can lower market costs, expand the reach
beyond routine clinical settings, and maximize resources by per-
forming multiplex testing. Partnerships between academia, indus-
try, and the Food and Drug Administration (FDA) may help
facilitate development of more adaptable guidance systems. The
goals of such a partnership should be fair to all manufacturers
and an affordable path to market for high quality tests. The field
could also benefit from academic and industry stakeholders pro-
viding support to the FDA to find ways to work within the regula-
tory environment while still meeting public health needs.
RESEARCH PRIORITIES, CONCLUSIONS, AND
FUTURE DIRECTION
Clinical Research Priorities
With regard to syphilis, key clinical research priorities in-
clude (i) antenatal TP screening and its impact on morbidity and
(ii) identifying syphilis infections in MSM requiring treatment.
Given that congenital syphilis continues to be of public health con-
cern with nearly 1 million pregnant women infected with syphilis
each year, a study of POC syphilis testing designed to demonstrate
improvements of birth outcomes in pregnant women who are
screened and treated for syphilis is needed.73 For studies directed
at treating MSM, incorporating a POC syphilis/HIV dual test
could be effective at early detection. However, as mentioned
above, for MSM populations, confirmatory tests may be needed
before treatment initiation given the persisting treponemal anti-
bodies. Hence, replacing blood tests for syphilis with multiplexing
POC diagnostic tests could facilitate earlier diagnosis of STIs.
Other antenatal screening priorities identified include tests for
CT and NG in pregnant women and their infants.
Other priorities discussed include the need to implement
POC diagnostic testing in primary care settings. As discussed
above (Implementation Barriers, Regulatory Challenges of New
Technology POCs), clinical and systemic attitudes towards POC
testing are generally not good due to POC implementation hurdles
and regulatory challenges. The question was raised whether an
existing screening approach, modeled on rapid POC influenza
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testing, could be used to implement POC STI testing. The working
group proposed the use of POC STI testing in urgent care settings
where patients expect real-time clinical management. As discussed,
STI etiological diagnosis and management has been challenging,
especially in resource-limited settings; hence, syndromic manage-
ment continues to be the primary approach recommended by pub-
lic health professionals for STI treatment.17,22,23 As a result, many
providers are not incentivized to find better methods for testing and
treatment. As noted above, syndromic management is ineffective,
leads to antimicrobial overuse, and likely furthers resistance.
Laboratory Research Priorities
One of the key questions identified was whether the use of
POC diagnostic tests with lower sensitivity is acceptable for use.
Such tests may be acceptable for use in certain settings where pa-
tients are not routinely tested or treated for STIs. In other words,
there is a need to balance the sensitivity of POC tests with overall
access to care.
In addition to an expansion of existing tests that perform
well, exciting new methods of pathogen detection were discussed.
The ability to miniaturize tests, multiplexing technologies, and
paper-based detection methods to reduce costs are all promising
approaches. In regards to nanotechnology, use of nanochords or
particles to amplify signals is promising development for POC
STI diagnostics. Nanotechnology could therefore be used to make
the detection of STIs better, faster, and easier.
Policy Priorities
A barrier to POC test development is how the current regu-
latory environment often makes it difficult to bring dual and mul-
tiplex diagnostic tests into practice. An additional challenge is in
the regulation of multiplexed tests, where FDA requirements for
analytical and clinical performance may be too stringent and in-
surmountable. It was therefore suggested that public/private part-
nerships could help inform changes to the FDA regulation of
multiplexing tests.
With respect to costs for POC diagnostics, the ideal price
point identified was about US $1.00 per test in low-resource set-
tings. Although making tests too inexpensive could deincentivize
production, higher costs could limit adoption of such tests in
developing countries. Consensus was that, in the United States,
an average cost of US $20.00 for diagnostics tests would
be reasonable.
In summary, although there is a clear and urgent need for
rapid POC diagnostics for STIs, the field is in its very early stages.
There are exciting new developments in diagnostic technology, but
limited demand and challenges in the regulatory approval of such
devices exist. Funders and developers will need vision and steady
motivation to bring new diagnostics forward. There is great poten-
tial for public health benefit with the advent of POC STI diagnos-
tics. When and how that potential will be realized, however,
remains to be seen.
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